• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物能预测联合免疫检查点阻断疗法的疗效和毒性吗?

Can gut microbes predict efficacy and toxicity of combined immune checkpoint blockade?

作者信息

Lam Khiem C, Goldszmid Romina S

机构信息

Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

出版信息

Cancer Cell. 2021 Oct 11;39(10):1314-1316. doi: 10.1016/j.ccell.2021.09.013.

DOI:10.1016/j.ccell.2021.09.013
PMID:34637746
Abstract

A recent report in Nature Medicine pinpoints a role for gut microbiota in response and toxicity to combined immune checkpoint blockade targeting CTLA-4 and PD-1. This emergent study provides insights that can be used to leverage microbiota in the design of anticancer therapies to mitigate toxicity while enhancing efficacy.

摘要

《自然·医学》最近的一份报告指出,肠道微生物群在针对CTLA-4和PD-1的联合免疫检查点阻断治疗的反应和毒性方面发挥着作用。这项新出现的研究提供了一些见解,可用于在抗癌治疗设计中利用微生物群,以减轻毒性同时提高疗效。

相似文献

1
Can gut microbes predict efficacy and toxicity of combined immune checkpoint blockade?肠道微生物能预测联合免疫检查点阻断疗法的疗效和毒性吗?
Cancer Cell. 2021 Oct 11;39(10):1314-1316. doi: 10.1016/j.ccell.2021.09.013.
2
Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review.揭示肠道微生物群在免疫检查点阻断治疗中的作用:一篇综述。
Semin Hematol. 2020 Jan;57(1):13-18. doi: 10.1053/j.seminhematol.2020.05.002. Epub 2020 May 19.
3
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.调节肠道菌群以克服癌症免疫治疗中免疫检查点阻断的耐药性。
Curr Opin Pharmacol. 2020 Oct;54:1-10. doi: 10.1016/j.coph.2020.06.004. Epub 2020 Jun 30.
4
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.肠道微生物组在癌症免疫治疗中的调节作用:免疫检查点抑制剂阻断的新范例。
Cancer Med. 2021 Feb;10(3):1141-1154. doi: 10.1002/cam4.3694. Epub 2020 Dec 25.
5
alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade.改变肠道微生物群,并在免疫检查点阻断的情况下调节 T 调节细胞的功能代谢。
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27509-27515. doi: 10.1073/pnas.1921223117. Epub 2020 Oct 19.
6
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.肠道微生物组特征与 CTLA-4 和 PD-1 联合阻断的毒性相关。
Nat Med. 2021 Aug;27(8):1432-1441. doi: 10.1038/s41591-021-01406-6. Epub 2021 Jul 8.
7
Mitigating gut immune adverse effects in CTLA-4 blockade for antitumor efficacy.减轻CTLA-4阻断中肠道免疫不良反应以提高抗肿瘤疗效。
Sci China Life Sci. 2024 Jul;67(7):1539-1541. doi: 10.1007/s11427-024-2550-4. Epub 2024 Apr 3.
8
How does the gut microbiome influence immune checkpoint blockade therapy?肠道微生物组如何影响免疫检查点阻断疗法?
Immunol Cell Biol. 2021 Apr;99(4):361-372. doi: 10.1111/imcb.12423. Epub 2020 Nov 22.
9
Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.共生微生物群有助于预测非小细胞肺癌患者对免疫检查点抑制剂的反应。
Cancer Sci. 2021 Aug;112(8):3005-3017. doi: 10.1111/cas.14979. Epub 2021 Jun 23.
10
Gut Microbiota in Cancer Immune Response and Immunotherapy.肠道微生物群在癌症免疫反应和免疫治疗中的作用。
Trends Cancer. 2021 Jul;7(7):647-660. doi: 10.1016/j.trecan.2021.01.010. Epub 2021 Mar 2.

引用本文的文献

1
Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy.肠道微生物群重塑肿瘤微环境并影响结直肠癌免疫治疗的疗效。
Cancer Med. 2025 Jun;14(12):e70994. doi: 10.1002/cam4.70994.
2
Gut microbiome for predicting immune checkpoint blockade-associated adverse events.肠道微生物组预测免疫检查点阻断相关不良事件。
Genome Med. 2024 Jan 19;16(1):16. doi: 10.1186/s13073-024-01285-9.
3
Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors.肠道微生物在免疫检查点抑制剂疗效和毒性中的潜在作用。
Front Pharmacol. 2023 Jun 21;14:1170591. doi: 10.3389/fphar.2023.1170591. eCollection 2023.
4
Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors.修订肺癌细胞因子诱导的杀伤细胞治疗领域:聚焦免疫检查点抑制剂。
Int J Mol Sci. 2023 Mar 15;24(6):5626. doi: 10.3390/ijms24065626.
5
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.将基于血液的PD-L1表达评估作为抗PD-(L)1免疫疗法生物标志物的挑战与不断演变的形势
Biomedicines. 2022 May 20;10(5):1181. doi: 10.3390/biomedicines10051181.